Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
Model scores of the 29,894 trials active now.
Model score 11% for any early termination, 7% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 22% of the time (376 trials).
Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.
How it ended
Completed on 2026-01-16, after 2011-07-18 start.
The score above never used this outcome: finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.
Termination over time, as the model saw it at the start
Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2026-01-16. The rest of the way to 100% is still running.
From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.
What moved the score
-
Design: crossover (lowers risk) · Design
-
Accepts healthy volunteers: No (raises risk) · Who can join
-
Sponsor's past termination rate: 10.7% (raises risk) · Sponsor's track record
-
Phase: 2 (raises risk) · Design
-
Maximum age: 120 (lowers risk) · Who can join
-
Wording of the registration (title, summary, criteria) (raises risk) · Wording
Phrases that raised it: determinesurgerygreaterheartprior
Phrases that lowered it: mmhgsinglesorafenibparticipantcross over -
Disease area, cancer: Yes (raises risk) · Disease area
-
Trials the sponsor started in the prior 2 years: 312 (raises risk) · Sponsor's track record
-
Drug's FAERS reports marked serious: 77.7% (lowers risk) · Drug's FDA history
-
Drug's FAERS reports with a death: 15.1% (lowers risk) · Drug's FDA history
-
Sponsor type: government (lowers risk) · Sponsor's track record
-
Sponsor's past trials: 521 (lowers risk) · Sponsor's track record
-
Primary purpose: treatment (raises risk) · Design
-
Drugs with FDA adverse-event history: 20 (raises risk) · Drug's FDA history
-
Has a data monitoring committee: No (lowers risk) · Design
-
Disease area, neurology: No (lowers risk) · Disease area
Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.
The trial
Design
- Phase
- 2
- Number of arms
- 2
- Allocation
- randomized
- Design
- crossover (typical: parallel)
- Primary purpose
- treatment
- Blinding
- none
- Has a data monitoring committee
- No (typical: 56% yes)
- Responsible party
- principal investigator (typical: sponsor)
- Collaborators
- 0
- Keywords listed
- 5 (typical: 1)
Who can join
- Minimum age
- 16 (typical: 18)
- Maximum age
- 120 (typical: 71)
- Sex
- all
- Accepts healthy volunteers
- No (typical: 9% yes)
Sponsor's track record
- Sponsor type
- government (typical: academic or other)
- Sponsor's past trials
- 521 (typical: 32)
- Sponsor's past termination rate
- 10.7% (typical: 9.9%)
- Trials the sponsor started in the prior 2 years
- 312 (typical: 19)
Drug's FDA history
- Drugs with FDA adverse-event history
- 20 (typical: 1)
- Drug has FAERS history
- Yes (typical: 64% yes)
- Drug's FAERS reports before start
- 323673 (typical: 2148)
- Drug's FAERS reports in the prior 12 months
- 73076 (typical: 412.5)
- Drug's FAERS reports marked serious
- 77.7% (typical: 85.6%)
- Drug's FAERS reports with a death
- 15.1% (typical: 15.9%)
Disease area and drugs
- Disease areas
- cancer
- Drugs matched to FDA substances
- acetaminophen, atropine diphenoxylate, cediranib, diazepam, diphenhydramine, diphenoxylate, estazolam, filgrastim
Typical values are among the trials active now. Sponsor and drug history are counted only up to this trial's start date.
Similar finished trials
- Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma NCT00942877 · started 2009 · scored riskier than 77% of active trials completed
- APX005M and Doxorubicin in Advanced Sarcoma NCT03719430 · started 2019 · scored riskier than 94% of active trials completed
- Ph II Nintedanib vs. Ifosfamide in Soft Tissue Sarcoma NCT02808247 · started 2017 · scored riskier than 84% of active trials terminated
- Sunitinib to Treat Recurrent Brain Cancer NCT00923117 · started 2008 · scored riskier than 45% of active trials terminated
- Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas NCT02978859 · started 2016 · scored riskier than 99% of active trials completed
Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.